Zydus, Prolong sign deal to develop anemia treatment

AHMEDABAD, India Zydus Cadila and Prolong Pharmaceuticals have signed a development deal for a therapeutic protein, PEG-EPO, for the treatment of severe anemia, according to published reports.

Under the terms of the deal, both companies will use Prolong’s PEGylation technology to make PEG-EPO.

Severe anemia is a condition where the hemoglobin level or number of circulating red blood cells is significantly reduced. This is common in chronic renal failure, cancer patients undergoing chemotherapy, chronic inflammatory diseases, heart failure, and critically ill patients.